Want to join the conversation?
Specialty biopharma company $EBS said that its military-grade auto-injector platform, Emergard, has been selected by the US DoD and the Battelle Memorial Institute to be tested against and developed to US military specifications as a platform for nerve agent antidote delivery. Emergard development and testing is expected to be completed in 2016.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.